Patents Assigned to Centocor Ortho Biotech Inc.
-
Patent number: 8759067Abstract: The present invention relates to potato virus NIa protease variants or fragments thereof, polynucleotides encoding them, and methods of making and using the foregoing.Type: GrantFiled: March 22, 2013Date of Patent: June 24, 2014Assignee: Centocor Ortho Biotech Inc.Inventors: Ellen Chi, Michael Hunter, Ronald Swanson
-
Patent number: 8728985Abstract: Methods are provided for the display of a complex homodimer protein on the surface of a bacteriophage particle and combinatorial synthetic libraries of such proteins displayed as a fusion polypeptide with filamentous phage pIX coat protein. Heterodimeric or more complex interchain bonded structure, such as disulfide-linked, multimeric proteins, may be displayed using the method of the invention.Type: GrantFiled: November 15, 2010Date of Patent: May 20, 2014Assignee: Centocor Ortho Biotech Inc.Inventors: Chichi Huang, Tracy Spinka-Doms, Johan Fransson
-
Patent number: 8618264Abstract: The present invention provides antibodies immunospecific for human CD147 capable of blocking bioactivity of CD147 associated with malignant disease such as the stimulation of MMPs from fibroblast cells by tumor cells, the release of VEGF, and the promotion of angiogenesis. The antibodies of the present invention of are useful in treating malignant disease and those diseases in which CD147 activity is plays a pathogenic role, such as diseases of the eye, lung, and cardiovascular system.Type: GrantFiled: August 19, 2009Date of Patent: December 31, 2013Assignee: Centocor Ortho Biotech Inc.Inventors: Mark Cunningham, Bethany Swencki-Underwood, Yi Tang, Li Yan
-
Patent number: 8614185Abstract: The present invention relates to melanocortin receptor binding conjugates and methods of making and using the foregoing.Type: GrantFiled: April 27, 2010Date of Patent: December 24, 2013Assignee: Centocor Ortho Biotech Inc.Inventor: George Heavner
-
Publication number: 20130196413Abstract: The present invention relates to potato virus NIa protease variants or fragments thereof, polynucleotides encoding them, and methods of making and using the foregoing.Type: ApplicationFiled: March 22, 2013Publication date: August 1, 2013Applicant: CENTOCOR ORTHO BIOTECH INC.Inventors: Ellen Chi, Michael Hunter, Ronald Swanson
-
Patent number: 8450086Abstract: Improved bacterial secretion signals derived from pelB and ompA are provided. The improved variants enhance bacterial membrane secretion are thus useful for production of proteins secreted from bacteria including proteins displayed on filamentous phage particles, and, in particular, proteins requiring oxidative formation of covalent bonds, such as disulfide bonds within or between polypeptide chains in order to form a correctly folded and functional protein structure. Described herein are methods for the multivalent display of complex dimeric proteins on the surface of a bacteriophage particle and combinatorial synthetic libraries of such proteins displayed as a fusion polypeptide with filamentous phage pIX coat protein. Heterodimeric or more complex interchain bonded structures may also be displayed using the method of the invention.Type: GrantFiled: November 15, 2010Date of Patent: May 28, 2013Assignee: Centocor Ortho Biotech Inc.Inventors: Chichi Huang, Lu Lu
-
Patent number: 8426186Abstract: The present invention relates to potato virus NIa protease variants or fragments thereof, polynucleotides encoding them, and methods of making and using the foregoing.Type: GrantFiled: April 14, 2011Date of Patent: April 23, 2013Assignee: Centocor Ortho Biotech Inc.Inventors: Ellen Chi, Michael Hunter, Ronald Swanson
-
Patent number: 8415291Abstract: A protein scaffold based on a consensus sequence of the tenth fibronectin type III (FN3) repeat from human fibronectin, preferably human Tenascin, that binds to human TNF? including isolated nucleic acids that encode a protein scaffold, vectors, host cells, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.Type: GrantFiled: October 27, 2009Date of Patent: April 9, 2013Assignee: Centocor Ortho Biotech Inc.Inventors: Steven Jacobs, Karyn O'Neil
-
Patent number: 8399630Abstract: The present invention relates to engineered antibodies immuno specific for human interleukin-13 (IL-13) protein or fragment thereof, as well as methods of making and using thereof, including therapeutic indications.Type: GrantFiled: August 11, 2009Date of Patent: March 19, 2013Assignee: Centocor Ortho Biotech Inc.Inventors: Ronald V. Swanson, Ellen Chi, Gopalan Raghunathan, Shanrong Zhao, Johan Fransson, Wendy Cordier, Hong Mimi Zhou, Juan C. Almagro, Linus Hyun, Jill Giles-Komar, Karyn T. O'Neil, Jill M. Carton, Alexey V. Teplyakov, Yiqing Feng
-
Patent number: 8338171Abstract: Polynucleotide sequences encoding a baboon homolog of human CD147 and polypeptides obtainable form the polynucleotides and uses are disclosed.Type: GrantFiled: August 12, 2010Date of Patent: December 25, 2012Assignee: Centocor Ortho Biotech Inc.Inventors: Bethany Swencki-Underwood, Michael Naso
-
Patent number: 8323646Abstract: The present invention relates to engineered antibodies immunospecific for human interleukin-13 (IL-13) protein or fragment thereof, as well as methods of making and using thereof, including therapeutic indications.Type: GrantFiled: August 12, 2009Date of Patent: December 4, 2012Assignee: Centocor Ortho Biotech Inc.Inventors: Ronald V. Swanson, Ellen Chi, Gopalan Raghunathan, Shanrong Zhao, Johan Fransson, Wendy Cordier, Hong Mimi Zhou, Juan C. Almagro, Linus Hyun, Jill Giles-Komar, Karyn T. O'Neil, Jill M. Carton, Alexey V. Teplyakov, Yiging Feng
-
Patent number: 8309688Abstract: Cytokine oncostatin M nucleic acids from Cynomolgus monkey are useful for expression of oncostatin M proteins that are functional homologs of human oncostatin M. The nucleic acids and proteins produced therefrom are useful in screening and safety testing of oncostatin M, the generation and testing of oncostatin M modulators and related activities.Type: GrantFiled: December 29, 2009Date of Patent: November 13, 2012Assignee: Centocor Ortho Biotech Inc.Inventors: Adam Cotty, Michael Naso
-
Patent number: 8293482Abstract: A protein scaffold based on a consensus sequence of the tenth fibronectin type III (FN3) repeat from human fibronectin, including isolated nucleic acids that encode a protein scaffold, vectors, host cells, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices. In particular, protein scaffold molecules binding to IgG based on the consensus sequence have been identified as useful for diagnostic and/or therapeutic applications.Type: GrantFiled: February 12, 2010Date of Patent: October 23, 2012Assignee: Centocor Ortho Biotech Inc.Inventors: Steven Jacobs, Karyn O'Neil
-
Patent number: 8278419Abstract: A protein scaffold based on a consensus sequence of fibronectin type III (FN3) proteins, such as the tenth FN3 repeat from human fibronectin (human Tenascin), including isolated nucleic acids that encode a protein scaffold, vectors, host cells, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices. In particular, protein scaffold molecules binding to IgG have been identified as useful for diagnostic and/or therapeutic applications.Type: GrantFiled: October 27, 2009Date of Patent: October 2, 2012Assignee: Centocor Ortho Biotech Inc.Inventors: Steven Jacobs, Karyn O'Neil
-
Publication number: 20120178100Abstract: The invention provides tools for management of patients diagnosed with psoriatic arthritis, specifically, prior to the initiation of therapy with an anti-TNF? agent. The tools are specific markers and algorithms of predicting response to therapy based on standard clinical primary and secondary endpoints using serum marker concentrations. In one embodiment the baseline levels of VEGF, prostatic acid phosphatase, and adiponectin are used to predict the response at Week 14 after the initiation of therapy. In another embodiment, the change in a serum protein biomarker after 4 weeks of therapy is used such as MDC, lipoprotein a, and beta2-microglobulin.Type: ApplicationFiled: July 12, 2010Publication date: July 12, 2012Applicant: CENTOCOR ORTHO BIOTECH INC.Inventors: Carrie Wagner, Sudha Visvanathan
-
Patent number: 8216842Abstract: The present invention provides methods of enhancing hybridoma fusion efficiencies through cell synchronization of the fusion partners, in order to aid in production of antibodies.Type: GrantFiled: October 12, 2007Date of Patent: July 10, 2012Assignee: Centocor Ortho Biotech Inc.Inventors: Jill Giles-Komar, Michael Rycyzyn, Gregory Bannish
-
Patent number: 8138315Abstract: An immunoliposome composition targeted to the alphaV-integrin subunit of integrin receptors comprised of ligand-targeted liposomes bearing at least one targeting-ligand derived from an antibody and having binding specificity for at least one integrin receptor comprising an alpha V subunit including ?v?1, ?v?3 ?v?5, ?v?6, or ?v?8 integrin cell receptors is described. The antibody-derived targeting ligand may be a Fab? fragment, a scFv, or the like. Binding of the immunoliposome to ?v-integrin expressing cells, preferably results in internalization of the immunoliposome for cytoplasmic delivery of a liposome-entrapped agent.Type: GrantFiled: May 11, 2011Date of Patent: March 20, 2012Assignee: Centocor Ortho Biotech Inc.Inventors: Joshua Goldstein, Allen Magill, Deepak Saini, Linda A. Snyder, Raymond Sweet, Steve P. Weng
-
Patent number: 8088600Abstract: The present invention relates to at least one novel cynomolgus IL-13 muteins (Mut-IL-13) proteins, antibodies, including isolated nucleic acids that encode at least one Mut-IL-13 protein or antibody, Mut-IL-13 vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.Type: GrantFiled: October 12, 2007Date of Patent: January 3, 2012Assignee: Centocor Ortho Biotech Inc.Inventors: Karyn O'Neil, Leslee Conrad, Dusti Fisher
-
Patent number: 8084232Abstract: Isolated polynucleotides encoding Papio cynocephalus Toll-Like Receptor 3 (Baboon TLR3), polypeptides obtainable from expression of these polynucleotides, recombinant cells, and methods of use are disclosed.Type: GrantFiled: September 30, 2009Date of Patent: December 27, 2011Assignee: Centocor Ortho Biotech Inc.Inventors: Jarrat Jordan, Jessica Schreiter, Bethany Swencki-Underwood
-
Patent number: RE43876Abstract: The present invention is directed to pluripotent cells that can be readily expanded in culture on tissue culture substrate that is not pre-treated with protein or an extracellular matrix, and do not require a feeder cell line. The present invention also provides methods to derive the pluripotent cell line from human embryonic stem cells.Type: GrantFiled: February 14, 2012Date of Patent: December 25, 2012Assignee: Centocor Ortho Biotech Inc.Inventor: Alireza Rezania